Ultragenyx Pharmaceutical Inc.
RARE
$35.11
-$0.87-2.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.99% | 29.42% | 42.27% | 35.75% | 8.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.99% | 29.42% | 42.27% | 35.75% | 8.30% |
| Cost of Revenue | -0.81% | 8.21% | 91.33% | 4.53% | 10.15% |
| Gross Profit | 36.75% | -3.15% | 36.07% | 46.27% | -12.56% |
| SG&A Expenses | 12.33% | 7.37% | 7.25% | -0.98% | 1.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.94% | 15.12% | 11.65% | 2.78% | 7.69% |
| Operating Income | 13.55% | -0.19% | 9.04% | 21.35% | -7.30% |
| Income Before Tax | 12.02% | -5.13% | 16.22% | 17.82% | -4.13% |
| Income Tax Expenses | 187.91% | 99.49% | -53.38% | 17.21% | -8.08% |
| Earnings from Continuing Operations | 11.49% | -8.28% | 16.37% | 17.66% | -4.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.49% | -8.28% | 16.37% | 17.66% | -4.09% |
| EBIT | 13.55% | -0.19% | 9.04% | 21.35% | -7.30% |
| EBITDA | 14.41% | 0.56% | 10.64% | 24.61% | -5.13% |
| EPS Basic | 22.52% | 8.20% | 37.24% | 32.58% | 13.09% |
| Normalized Basic EPS | 24.73% | 13.19% | 36.24% | 34.87% | 10.97% |
| EPS Diluted | 22.52% | 8.20% | 37.24% | 32.58% | 13.09% |
| Normalized Diluted EPS | 24.73% | 13.19% | 36.24% | 34.87% | 10.97% |
| Average Basic Shares Outstanding | 14.24% | 17.95% | 33.25% | 22.12% | 19.78% |
| Average Diluted Shares Outstanding | 14.24% | 17.95% | 33.25% | 22.12% | 19.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |